NCT02421536 is a NA clinical trial of Vibrogent Smartphone Application in Mucositis, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT02421536?

NCT02421536 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT02421536?

Interventions in NCT02421536: Vibrogent Smartphone Application.

Is NCT02421536 still recruiting?

NCT02421536 is currently completed. Last updated 17 January 2023.

Last reviewed 2023-01-17 · How we verify

NCT02421536

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vibrent Smartphone Mobile Application

Completed NA Last updated 17 January 2023

What this trial tests

NA trial testing Vibrogent Smartphone Application in Mucositis in 48 participants. Completed in 31 December 2022.

Timeline

14 January 2016

Primary endpoint
26 April 2018

31 December 2022

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	48
Start date	14 January 2016
Primary completion	26 April 2018
Estimated completion	31 December 2022
Sites	1 location across United States

Drugs / interventions tested

Vibrogent Smartphone Application

Conditions studied

Mucositis — all drugs for Mucositis →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 100, any sex, with Mucositis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research is being done to evaluate whether or not a customized version of the VibrentTM (formerly FitNinjaTM) mobile app is a feasible way to help people manage and control the pain from radiation sores (also referred to as "mucositis") when treating head and neck cancers with radiation. The mobile app will be designed to help people better understand the pain from the radiation sores and how to better use their medications especially when they are away from the hospital.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Beyond the Randomized Controlled Trial: A Review of Alternatives in mHealth Clinical Trial Methods.
Pham Q, Wiljer D, Cafazzo JA. · · 2016 · cited 113× · PMID 27613084 · DOI 10.2196/mhealth.5720

Verify or expand the search:

Other recruiting trials for Mucositis

Currently open trials in the same condition.

NCT06599346 — Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin/Mucosal Injury in Hematology Patients · NA · recruiting
NCT03581773 — Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients R · Phase 2 · recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02421536 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 17 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02421536.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing